Status:
COMPLETED
NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborating Sponsors:
Ministry of Science and Technology, Taiwan
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-100 years
Phase:
PHASE2
Brief Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR) were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This study is a ra...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Alzheimer's disease
- MMSE between 10-26
- CDR 1
Exclusion
- Hachinski Ischemic Score \> 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
Key Trial Info
Start Date :
May 22 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT03752463
Start Date
May 22 2015
End Date
July 31 2021
Last Update
August 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886